Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 4737-4752

  Stanford, Jamie C ^a   Young, Christian ^b   Hicks, Donna ^a   Owens, Philip ^a   Williams, Andrew ^a   Vaught, David B ^a   Morrison, Meghan M ^a   Lim, Jiyeon ^a   Williams, Michelle ^a   Brantley Sieders, Dana M ^b   Balko, Justin M ^b   Tonetti, Debra ^c   Earp, H Shelton ^d   Cook, Rebecca S ^a,e  

^a Department of Cancer Biology ^*  (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 777607; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOKINE; MERTK PROTEIN, MOUSE; ONCOPROTEIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CANCER GRAFT; CANCER TRANSPLANTATION; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; EFFEROCYTOSIS; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; INVOLUTION; LUNG METASTASIS; MALE; MAMMARY GLAND; METASTASIS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; NULLIPARA; PUERPERIUM; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WOUND HEALING; ANIMAL; APOPTOSIS; COCULTURE; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHAGOCYTOSIS; SECONDARY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR VOLUME; UDDER; UPREGULATION;

ANIMALS; APOPTOSIS; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS; POSTPARTUM PERIOD; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR BURDEN; UP-REGULATION;

EID: 84908637378     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76375     Document Type: Article

References (70)

1. Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004; 112(2):306-311.
2. Pathak DR. Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Causes Control. 2002;13(4):295-298.
3. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: When they collide. J Mammary Gland Biol Neoplasia. 2009;14(2):87-98.
4. Martinson HA, Lyons TR, Giles ED, Borges VF, Schedin P. Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention. Exp Cell Res. 2013; pii(11):S0014-4827(13)00189-4.
5. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006; 6(4):281-291.
6. Schedin PJ, Watson CJ. The complexity of the relationships between age at first birth and breast cancer incidence curves implicate pregnancy in cancer initiation as well as promotion of existing lesions. Preface. J Mammary Gland Biol Neoplasia. 2009;14(2):85-86.
7. Callihan EB, et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2013;138(2):549-559.
8. Faupel-Badger JM, et al. Postpartum remodeling, lactation, and breast cancer risk: Summary of a National Cancer Institute-sponsored workshop. J Natl Cancer Inst. 2013;105(3):166-174.
9. Amant F, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31(20):2532-2539.
10. Lyons TR, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med. 2011;17(9):1109-1115.
11. McDaniel SM, et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol. 2006;168(2):608-620.
12. Schedin P, O'Brien J, Rudolph M, Stein T, Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia. 2007;12(1):71-82.
13. O'Brien J, Schedin P. Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J Mammary Gland Biol Neoplasia. 2009;14(2):145-157.
14. O'Brien JH, Vanderlinden LA, Schedin PJ, Hansen KC. Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis. J Proteome Res. 2012;11(10):4894-4905.
15. Schedin P, Borges V. Breaking down barriers: The importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Breast Cancer Res. 2009;11(2):102.
16. O'Brien J, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol. 2010;176(3):1241-1255.
17. Fornetti J, Jindal S, Middleton KA, Borges VF, Schedin P. Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young women. Am J Pathol. 2014;184(4):1219-1229.
18. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33(3):119-126.
19. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
20. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science. 2013;339(6117):286-291.
21. Denardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54-67.
22. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.
23. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211-217.
24. Kristensen VN, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA. 2012;109(8):2802-2807.
25. Faghih Z, Erfani N, Haghshenas MR, Safaei A, Talei AR, Ghaderi A. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett. 2014;158(1):57-65.
26. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004;6(2):R92-R109.
27. Asztalos S, et al. Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila). 2010;3(3):301-311.
28. Stein T, Salomonis N, Nuyten DS, van de Vijver MJ, Gusterson BA. A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2009;14(2):99-116.
29. Flanders KC, Wakefield LM. Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia. 2009;14(2):131-144.
30. Sandahl M, Hunter DM, Strunk KE, Earp HS, Cook RS. Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation. BMC Dev Biol. 2010;10:122.
31. Cook RS, et al. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest. 2013;123(8):3231-3242.
32. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954-961.
33. Kreuzaler PA, et al. Stat3 controls lysosomalmediated cell death in vivo. Nat Cell Biol. 2011;13(3):303-309.
34. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol. 2007;178(9):5635-5642.
35. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol. 2012;189(7):3508-3520.
36. Schroeder GM, et al. Discovery of N-(4-(2- Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)- 4-ethoxy-1-(4-fluorophenyl )-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem. 2009;52(5):1251-1254.
37. Stein T, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res. 2004;6(2):R75-R91.
38. Wallet MA, et al. MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med. 2008;205(1):219-232.
39. Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci. 2010;1209:23-29.
40. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131(6):1124-1136.
41. Clarkson RW, Watson CJ. Microarray analysis of the involution switch. J Mammary Gland Biol Neoplasia. 2003;8(3):309-319.
42. Watson CJ. Immune cell regulators in mouse mammary development and involution. J Anim Sci. 2009;87(13):35-42.
43. Teschendorff AE, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer. 2010;10:604.
44. Park HJ, Baen JY, Lee YJ, Choi YH, Kang JL. The TAM-family receptor Mer mediates production of HGF through the RhoA-dependent pathway in response to apoptotic cells. Mol Biol Cell. 2012;23(16):3254-3265.
45. O'Brien J, Martinson H, Durand-Rougely C, Schedin P. Macrophages are crucial for epithelial cell death and adipocyte repopulation during mammary gland involution. Development. 2012;139(2):269-275.
46. Hughes K, Wickenden JA, Allen JE, Watson CJ. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. J Pathol. 2012;227(1):106-117.
47. Vandivier RW, Henson PM, Douglas IS. Burying the dead: The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest. 2006;129(6):1673-1682.
48. deCathelineau AM, Henson PM. The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays Biochem. 2003;39:105-117.
49. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ. 2008;15(2):243-250.
50. Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol. 2011;41(9):2515-2518.
51. Fullerton JN, O'Brien AJ, Gilroy DW. Pathways mediating resolution of inflammation: When enough is too much. J Pathol. 2013;231(1):8-20.
52. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148(7):2207-2216.
53. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest. 1998;101(4):890-898.
54. Filardy AA, et al. Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low) IL-10(high) regulatory phenotype in macrophages. J Immunol. 2010;185(4):2044-2050.
55. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine- dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002;109(1):41-50.
56. DeNardo DG, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91-102.
57. Gong D, Shi W, Yi SJ, Chen H, Groffen J, Heisterkamp N. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012;13:31.
58. Wan E, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelialreproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res. 2013;113(8):1004-1012.
59. Choi JY, et al. Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide- induced lung inflammation. J Pharmacol Exp Ther. 2013;344(2):447-458.
60. Kazeros A, Harvey BG, Carolan BJ, Vanni H, Krause A, Crystal RG. Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers. Am J Respir Cell Mol Biol. 2008;39(6):747-757.
61. Gautier EL, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13(11):1118-1128.
62. Patin E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology. 2012;143(5):1244-1252.
63. Loges S, et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood. 2010;115(11):2264-2273.
64. Linger RM, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2013;32(29):3420-3431.
65. Whitman SP, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014;28(6):1252-1258.
66. Keating AK, et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther. 2010;9(5):1298-1307.
67. Scott RS, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001;411(6834):207-211.
68. Cook RS, et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 2011;71(11):3941-3951.
69. Vaught DB, et al. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012;72(10):2672-2682.
70. Candolfi M, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res. 2009;15(13):4401-4414.